Organization (Hospital)
RADY CHILDREN'S HOSPITAL SAN DIEGO
ClinicalTrials.gov lists RADY CHILDREN'S HOSPITAL SAN DIEGO as lead sponsor of 11 trials. It has 1 active development program and 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers RADY CHILDREN'S HOSPITAL SAN DIEGO: 11 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (65)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Autism Spectrum Disorder | 4 |
| Angelman Syndrome | 3 |
| Diabetes Mellitus | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Emergencies | 2 |
Showing 5 of 65 disease areas.
Trials by start year as sponsor or collaborator (22)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 4 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 4 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 3 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 2 |
Showing 10 of 22 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| (R,S)-ketamine (Pilot I) | Emergencies | Early 1 | 1 |
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Ciclopirox | 1 |
| (R,S)-ketamine (Pilot I) | 1 |
| DEXAMETHASONE | 1 |
| Cisatracurium | 1 |
Journals published in (64)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association | 5 |
| The Journal of pediatrics | 5 |
| Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery | 4 |
| Sensors (Basel, Switzerland) | 3 |
| American journal of medical genetics. Part A | 2 |
Showing 5 of 64 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1 | 0 | 2014-10-14 |
Organization relationships (112)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of California System | Co sponsors trial with | 8 |
| Boston Children's Hospital | Co sponsors trial with | 7 |
| Cincinnati Children's Hospital Medical Center | Co sponsors trial with | 6 |
| Children's Hospital of Philadelphia | Co sponsors trial with | 6 |
| Harris Health System | Co sponsors trial with | 6 |
Showing 5 of 112 relationships.
Latest dated events (47)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-08-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-03-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 47 events.
CLIA clinical laboratory certificates (5)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| RADY CHILDREN'S HOSPITAL - SAN DIEGO | Certificate of accreditation | Active |
| RADY CHILDREN'S HOSPITAL - SAN DIEGO | Certificate of waiver | Active |
| RADY CHILDREN'S HOSPITAL SAN DIEGO | Certificate of waiver | Active |
| RADY CHILDREN'S HOSPITAL SAN DIEGO | Certificate of waiver | Active |
| RADY CHILDREN'S HOSPITAL SAN DIEGO | Certificate of waiver | Terminated |
Biomarker capability evidence (703)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AAAS | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| AARS1 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| ABCA3 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| ABCB4 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| ABCC2 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
Showing 5 of 703 evidence rows.
Biomarkers this organization publishes on (129)
Shown in this order: most publications first.
Showing 5 of 129 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.